📰 $SAVA – CASSAVA SCIENCES TOPLINE PHASE 3 DATA DID NOT MEET CO-PRIMARY ENDPOINTS CASSAVA SCIENCES INC: SIMUFILAM CONTINUED TO DEMONSTRATE AN OVERALL FAVORABLE SAFETY PROFILE CASSAVA SCIENCES INC: SIMUFILAM DID NOT SHOW A SIGNIFICANT REDUCTION IN COGNITIVE OR FUNCTIONAL DECLINE VERSUS PLACEBO